logo
logo

IONpath Closes $18 Million Series B Financing to Advance Precision Medicine

Sep 24, 2020•almost 5 years ago

Amount Raised

$18 Million

Round Type

series b

Menlo ParkScience And EngineeringHealth Care

Description

 IONpath, Inc., the leader in high-definition spatial proteomics, today announced the close of a $18 million Series B financing led by Samsara BioCapital, and included participation from new investor Bruker Corporation, a global leader in mass spectrometry. All existing major investors contributed to the round including Genoa Ventures, ND Capital, Paladin Partners Investments, Trancos IONpath Investors, Norwich Ventures, and Vertical Venture Partners Growth Fund.

Company Information

Company

Io Npath, Inc. And Io Npath Research Services

Location

Menlo Park, California, United States

About

Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People